PDCD1 and non-small cell lung carcinoma: Additionally, combining CAR-T cell therapy with immune checkpoint inhibitors, such as anti-PD-1 or anti-CTLA-4 antibodies, has shown promise in preclinical and early-phase clinical trials for NSCLC.